According to INmune Bio's latest financial reports the company has a price-to-book ratio of 11203.1.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | 3.21 | -39.63% |
2023-12-31 | 5.32 | 181.07% |
2022-12-31 | 1.89 | -16.56% |
2021-12-31 | 2.27 | -62.13% |
2020-12-31 | 5.99 | 126.39% |
2019-12-31 | 2.65 | |
2018-12-31 | N/A | |
2017-12-31 | N/A |